Falling sales, rising competition behind Lilly/Chugai move to end Japan Evista pact?
This article was originally published in Scrip
Executive Summary
Lilly and Roche's Japanese affiliate Chugai have decided to discontinue their agreement for the co-marketing in Japan of Lilly's osteoporosis drug Evista (raloxifene), the move apparently being prompted by changing commercial priorities at both firms.